No­var­tis to seek ac­cel­er­at­ed ap­proval for oral com­ple­ment in­hibitor in rare kid­ney dis­ease

No­var­tis said that its ex­per­i­men­tal com­ple­ment in­hibitor ip­ta­co­pan re­duced the buildup of pro­tein in the urine of pa­tients with IgA nephropa­thy sig­nif­i­cant­ly more than a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.